Necitumumab

Necitumumab
Necitumumab Fab (blue) bound to EGFR (green). PDB: 6B3S​
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetEGFR
Clinical data
Trade namesPortrazza
AHFS/Drugs.comMultum Consumer Information
License data
Routes of
administration		Intravenous infusion
ATC code
Legal status
Legal status
Pharmacokinetic data
Elimination half-life~14 days
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6436H9958N1702O2020S42
Molar mass144844.87 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[3] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[4][5][2] It was counterproductive in non-squamous non-small-cell lung carcinoma.[2][6]

References

  1. ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
  2. ^ a b c "Portrazza- necitumumab solution". DailyMed. 15 December 2023. Retrieved 26 October 2024.
  3. ^ International Nonproprietary Names for Pharmaceutical Substances (INN, prepublication copy), World Health Organization.
  4. ^ Chustecka Z (2015-11-22). "Necitumumab (Portrazza) Approved for Lung Cancer in US". Medscape.com. Retrieved 2019-09-28.
  5. ^ "Necitumumab". Approved Drugs. U.S. Food and Drug Administration. Archived from the original on 2017-01-11. Retrieved 2019-12-16.
  6. ^ Hand L (3 March 2015). "Necitumumab Fails in NSCLC". MedScape. Archived from the original on 2015-11-29. Retrieved 2015-11-25.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.